BPC-157 10mg (Body Protection Compound-157)

The name is short for Body Protection Compound-157. The parent molecule, body protection compound or BPC, occurs naturally in the human digestive tract, where it keeps the lining of the gastrointestinal tract intact, supports repair once that lining has been damaged, and encourages the growth of new blood vessels.

BPC-157 itself is a pentadecapeptide: a 15 amino acid stretch isolated from that much larger protein and then made synthetically. For its size it carries over a good deal of the parent molecule's repair activity. Published work reports effects on:

Wound healing, blood vessel growth, the coagulation cascade, nitric oxide generation, immune system function, gene expression, and hormone regulation, the last of these particularly within the gastrointestinal nervous system.

BPC-157 is a synthetic 15 amino acid sequence, GEPPPGKPADDAGLV, derived from a region of a protein found in human gastric juice. It is described in the literature as a stable gastric pentadecapeptide, and the stability claim is specific rather than promotional: the peptide resists degradation in human gastric juice for hours, which is unusual for a peptide of this size and is the property that permitted the oral and intragastric routes used across the rodent literature.

No single receptor has been identified for it. That absence is the central fact of its pharmacology and the main reason the mechanism remains contested. What the published work describes instead is modulation of several systems at once, with the nitric oxide system appearing most consistently: BPC-157 interacts with both the L-arginine to nitric oxide pathway and its inhibition, and much of the animal work is designed around counteracting the effects of nitric oxide synthase blockade or of excess nitric oxide donors.

The second recurring theme is angiogenesis. Studies report upregulation of vascular endothelial growth factor receptor 2 signalling and accelerated formation of collateral vessels, which is the proposed basis for the healing effects described across widely different tissues. A third strand concerns growth factor receptor expression, including increased growth hormone receptor expression in tendon fibroblasts, offering a route by which a systemic peptide could influence a local repair process.

In the gut, the job of BPC is to keep the mucosal barrier sound. That barrier shields the tissue beneath it from gastric acid, bile and the other aggressive compounds that digestion and nutrient absorption depend on. Recruitment of fibroblasts accounts for at least part of how it does so.

The effect on fibroblast spread is dose-dependent, in culture and in vivo alike, with the cells both proliferating and migrating faster[1]. That is what ties the peptide to wound closure: fibroblasts are the cells that lay down the extracellular matrix, meaning collagen, fibrin, elastin and the rest.

BPC-157 behaves as a potent angiogenic factor, raising the rate at which endothelial cells, the lining cells of blood vessels, proliferate and grow[1]-[3]. In rats it substantially increases collateral vessel growth where tissue has been made ischemic[4]. Most of that work was done in the GI tract, but comparable results have been reported in cardiovascular, neurological and muscle tissue, which is why the peptide is discussed both as a candidate therapy after stroke or heart attack and as a probe for working out how ischemic tissue can be brought to repair itself[5], [6].

Chicken embryo studies point to VEGFR2 as at least part of the route by which it does this. VEGFR2 is a cell surface receptor active in the nitric oxide signalling pathway, and it is thought to govern endothelial cell growth, proliferation and longevity[4], [7], [8]. Vascular "running" following administration of the peptide has been demonstrated directly in cell culture[9].

If that activity holds up, it opens a route toward an orally available treatment for the slow-forming arterial occlusions seen in atherosclerotic heart disease.

Fibroblast recruitment and new vessel growth are the two things connective tissue repair is short of, so the positive findings in animal models of tendon, ligament, bone and other connective tissue injury follow fairly directly. Injuries to tendon and ligament heal slowly in large part because the blood supply to those tissues is poor.

Rat tendon work, both in vitro and in vivo, reports increased collateralization and higher fibroblast density after tendon, ligament and bone injury. In those comparisons BPC-157 promoted healing more effectively than the bFGF, EGF and VEGF hormones[10].

FITC-phalloidin staining shows it to be a strong stimulator of F-actin formation in fibroblasts[11]. F-actin underpins cell structure and function and is central to how a cell migrates. Western blotting adds a second step in the same pathway: increased phosphorylation of paxillin and FAK, two proteins the cell migration pathway cannot do without[12].

In rats, BPC-157 neutralises certain markers of oxidative stress, among them nitric oxide and malondialdehyde (MDA)[3]. Separate work showing reduced production of reactive oxygen species in the gastrointestinal tract is what makes a reading of powerful antioxidant activity defensible rather than an artefact of one assay.

One line of work has asked whether modified Lactococcus lactis bacteria could deliver the peptide to the GI system directly. In cell culture the engineered bacteria raised peptide levels dramatically[13].

What limits how long a pharmaceutical can be given is usually its side effects rather than its efficacy. Ibuprofen and the other NSAIDs are the familiar case: they cannot be taken for long stretches because they raise the risk of gastric bleeding and of heart attack. BPC-157 has been found to counteract side effects from NSAIDs, from medications used in psychiatric conditions, and from a number of heart medications.

Protection against the gastrointestinal side effects is the expected half, given where the parent protein does its work. Less intuitive is that it reaches the brain, the heart and other tissues as well. In rats the peptide protected against QTc prolongation, a change in cardiac conduction that can lead to serious and even fatal arrhythmias and that is caused by drugs used to treat diabetes, schizophrenia and other psychiatric conditions[14].

Other side effects of psychiatric medication were prevented in the same way, the severe ones among them, including catalepsy and somatosensory disturbance[15].

Colony collapse disorder, or CCD, is a syndrome in which an entire honey bee colony declines rapidly and is eventually destroyed outright. Supplementing the bees' feed with BPC-157 reduced the damage the fungus Nosema ceranae does to their GI tracts, and hive survival rates rose alongside that[16].

Those trials were run in natural field settings rather than a laboratory, and they represent the first oral treatment of any significance for limiting the impact of CCD on the insect that pollinates most food crops.

BPC-157 has a large literature by publication count and a narrow one by independent replication. A substantial share of the primary work originates from a small number of collaborating groups, largely in Croatia, and much of it appears in a limited set of journals.

This is not an accusation of error. It is a statement about how evidence accumulates. A finding reproduced by groups with different assumptions, reagents and incentives is more robust than the same finding repeated within one programme, however carefully that programme is run.

The practical consequence for a researcher is that effect sizes from this literature should be treated as provisional, and that independent replication in a new laboratory is a meaningful contribution rather than a redundant one.

For most peptides discussed on this catalogue, the mechanism begins with a named receptor. For BPC-157 there is no such starting point. No specific receptor has been cloned or characterised, and the mechanistic literature consists of observed interactions with systems, principally nitric oxide signalling and angiogenic pathways, rather than a defined ligand-receptor event.

That gap explains the unusual shape of the claims made for it. A compound acting at a known receptor produces effects predictable from that receptor's distribution. A compound with no identified receptor, reported to help in tendon, gut, brain and vessel alike, is either acting on something very general or is being over-attributed. The literature does not currently distinguish those possibilities.

Treating the absence of a receptor as an open question rather than an inconvenience is the honest reading, and it is the reason this compound sits differently from the incretin analogues elsewhere in this catalogue.

There is no approved BPC-157 product in any jurisdiction. Early clinical work was conducted under the code PL 14736 for inflammatory bowel indications and did not produce an approved medicine. There are no adequately powered, independently replicated human efficacy trials for the musculoskeletal uses most often discussed.

The gap between the volume of rodent literature and the near-absence of human trial data is the single most important thing to hold in view when reading about this peptide. Animal healing models are informative about mechanism and poorly predictive of human clinical outcomes.

Material supplied for research is for in-vitro laboratory use only. It is not a medicine and none of the work summarised here constitutes guidance for use in humans or animals.

BPC-157 is a short, highly proline-rich sequence containing three consecutive prolines. That composition makes it conformationally constrained and contributes to its resistance to proteolysis, and it also affects chromatographic behaviour, since proline-rich peptides can show cis-trans isomerism that broadens or splits peaks.

A broadened or split peak on an HPLC trace for a proline-rich peptide is therefore not automatically evidence of an impurity. Interpreting a purity figure for this sequence requires knowing the method conditions, which is one more reason the stated method on a certificate matters as much as the percentage.